Participated · Series A · Feb 2026

Minneapolis-based Pharaoh Neuro is a medical device company advancing two key technologies: the Neurapheresis cerebrospinal fluid (CSF) management system and the MindsEye expandable port for minimally invasive cranial access. Neurapheresis is a closed-loop platform that circulates and filters a patient’s own CSF without introducing replacement fluids, aiming to reduce complications and give clinicians greater control in treating critically ill neurological patients. MindsEye, first cleared by the FDA in 2020 while under Minnetronix Medical, is being prepared for reintroduction to the U.S. market under Pharaoh Neuro’s stewardship. The company recently appointed Amaza Reitmeier, former VP & GM of Neuromodulation at Medtronic, as CEO, and Dr. Nandan Lad, the inventor of the core technology, as chief medical officer. With its newly raised funds, Pharaoh Neuro plans to pursue further development and regulatory clearance for Neurapheresis and to relaunch MindsEye. The leadership’s stated goal is to reshape the standard of neurocritical care through evidence-based clinical introduction of its platform.

Participated · Series B · Nov 2025

Santa Barbara-based Sovato provides software and connectivity that lets health systems safely scale telesurgery programs by linking expert surgeons to distant robotic surgical systems. The platform is device-agnostic, already integrated with several leading robots, and has proven safety and feasibility in pre-clinical cases conducted hundreds to thousands of miles apart both domestically and internationally. By allowing a hub-and-spoke model in which one surgical team can serve multiple sites, Sovato helps address global surgeon shortages and geographic disparities in care. The company is collaborating with healthcare providers, robotic manufacturers, and standards bodies to establish operational guidelines for remote robotic surgery programs. Market tailwinds are strong, with the global robotic surgery sector projected to grow 12.4% annually through 2030 and more than 246 companies active in the space. Founded by Cynthia Perazzo and surgical robotics pioneer Dr. Yulun Wang, Sovato has raised $41 million to date, including its recent Series B, to accelerate product development and deepen industry partnerships.

Participated · Series B · Sep 2024

CorFlow Therapeutics is developing the CoFl system to provide timely, accurate detection of microvascular obstruction (MVO) in the cath lab immediately after stent implantation and to enable localized delivery of therapeutics to the microvasculature. The technology integrates with standard guide catheter and wire access and is intended to both diagnose MVO and deliver treatments at the point of care. CorFlow has reported recent data from over 70 patients in its first-in-human MOCA I trial and an extensive preclinical program supporting its approach. The company plans a MOCA II pivotal IDE trial in the US and Europe to validate CoFl against contrast-enhanced cardiac MRI and to support US market clearance. It will also run an adaptive platform therapy study in Europe to evaluate multiple therapeutic agents delivered via CoFl and measure clinical and imaging outcomes up to six months. Headquartered in Baar, Switzerland and founded in 2016, CorFlow is collaborating with academic partners including the University of Bern, ETH Zurich and University Hospital Zurich. CorFlow Therapeutics develops the Controlled Flow Infusion (CoFITM) system and a proprietary dynamic Microvascular Resistance (dMVRTM) concept to detect and treat microvascular obstruction (MVO) in the cathlab. The CoFITM system is positioned as a combined diagnostic and therapeutic technology that enables detection and low-flow infusion treatment of MVO immediately after reopening epicardial arteries. Seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) safety and feasibility trial in 40 acute heart attack patients. MOCA I will measure peri-procedural dMVR and compare those values to post-procedure contrast-enhanced MRI, and will investigate low-flow infusion of approved therapeutic agents to reduce MVO. The company cites that around 50% of acute heart attack patients develop MVO, translating to roughly 200,000 patients annually, and notes MVO is an independent predictor of heart failure and death. CorFlow has presented nonclinical data at major cardiology meetings (ACC, EuroPCR, ESC) and plans further presentation at TCT; it aims to raise a Series A in 2019 to secure longer-term R&D, clinical, and regulatory activities. CorFlow Therapeutics is developing proprietary technologies to diagnose and treat microvascular obstructions (MVO) in severe heart attack patients. Its technologies aim to enable interventional cardiologists to diagnose and treat MVO, potentially reducing short- and long-term complication rates. The company is led by CEO and co-founder Jon H. Hoem. Headquartered in Baar, Switzerland, CorFlow has raised more than CHF5M in seed funding to date. It completed a CHF 2.6M first close of a Seed+ round to advance clinical development. The company plans to use the funds to finance the 80-patient First-in-Man MOCA (MVO with CoFI™ System Assessment) clinical trial in Europe and intends the Seed+ as the basis for a larger Series A to secure long-term R&D, clinical, and regulatory activities.

Participated · Series A · Jul 2024

Novocuff develops the Novocuff Cervical Control System (CCS), a medical device designed to stabilize and close the cervix to retain amniotic fluid and sustain cervical length with the goal of extending pregnancy. The company is focused on improving pregnancy outcomes and reducing preterm births caused by PPROM and cervical shortening. Novocuff says it aims to transform the standard of care and bring the device to global markets, including low- and middle-income countries. Proceeds from an oversubscribed $26 million Series A will fund team expansion, a U.S. multi-center pivotal clinical trial planned for early 2025, pursuit of marketing authorization, and early-stage commercialization. The company completed an initial $2 million seed round prior to the Series A and has added clinical hires Kathryn Wine (VP, Clinical Affairs) and Marissa VanDeVeer (Clinical Engineer). Novocuff frames its work against the global burden of preterm birth, citing WHO data that preterm complications caused roughly 1 million infant deaths in 2020.

Led · Equity · Apr 2024

Avive Solutions develops the Avive Connect AED, a connected automated external defibrillator, alongside complementary software. The Avive Connect AED emphasizes portability, accessibility and connectivity and is paired with the REALConnect platform to streamline AED ownership and management. Avive also provides an intelligent response platform designed to deliver comprehensive cardiac arrest response capabilities to communities. The company is led by CEO Sameer Jafri and is based in San Francisco. In April 2024 Avive closed a $56.5M Growth Equity financing to support its commercial expansion. The company plans to use the proceeds to accelerate U.S. commercial developments and to expand its team with additional talent. Avive Solutions is a healthcare technology company building a connected automated external defibrillator (AED) paired with a software platform that integrates with public safety and provider ecosystems to address out-of-hospital cardiac arrest (OHCA). The platform connects with 911 Emergency Communications Centers via a partnership with RapidSOS and provides incident data-sharing to close data gaps during cardiac arrest responses. Avive has developed the "4-Minute City" program, which places AEDs strategically across municipalities combined with community training to promote early intervention and equitable outcomes. The company aims to increase survival rates from cardiac arrest and reduce disparities tied to socioeconomic and demographic factors. Led by co-founder and CEO Sameer Jafri and based in San Francisco, Avive closed a $22M Series A to advance its technology-enabled approach to improving OHCA survival rates. Avive Solutions is a San Francisco–based healthcare technology company developing a next-generation AED paired with a first-of-its-kind platform to revolutionize out-of-hospital cardiac arrest response. The company aims to increase SCA survival rates by combining advanced, affordable hardware with data-driven software and integrations into the emergency response ecosystem. Avive emphasizes accessible CPR training features, rapid defibrillation workflows, and a data link to professional first responders. Funding will be used to prepare for commercial launch pending FDA approval and to accelerate platform development and ecosystem integrations. Founded in 2017, Avive has raised over $15 million to date and is in the midst of the FDA review cycle. The company situates its product strategy around shortening time-to-defibrillation to address U.S. out-of-hospital SCA, which accounts for over 350,000 deaths annually and has national average survival rates below 10%. Revive Solutions is a San Francisco-based healthcare technology company developing a next-generation automated external defibrillator and accompanying software aimed at increasing survival from sudden cardiac arrest. The product is described as ultra-portable, easy to maintain, affordable, and simple for bystanders to use effectively. Revive positions its device to address limited AED accessibility caused by bulk, intimidating interfaces, maintenance burdens, and high price points. Proceeds from the recent financing will be used to complete the regulatory submission and pursue commercial launch upon FDA approval. The company emphasizes bringing a modernized, accessible AED to market to improve stagnant survival rates. To date, Revive has raised over $6M.